Published in Exp Ther Med on March 01, 2010
Prospective virtual screening for novel p53-MDM2 inhibitors using ultrafast shape recognition. J Comput Aided Mol Des (2014) 0.85
Clinically relevant doses of candesartan inhibit growth of prostate tumor xenografts in vivo through modulation of tumor angiogenesis. J Pharmacol Exp Ther (2014) 0.83
Telmisartan induces growth inhibition, DNA double-strand breaks and apoptosis in human endometrial cancer cells. PLoS One (2014) 0.80
Telmisartan induces apoptosis and regulates Bcl-2 in human renal cancer cells. Exp Biol Med (Maywood) (2014) 0.80
Antiproliferative and apoptotic effects of telmisartan in human colon cancer cells. Oncol Lett (2014) 0.79
Lack of an association between angiotensin receptor blocker based therapy and increased risk of cancer: evidence from large observational studies. PLoS One (2015) 0.78
Angiotensin II type 1 receptor blocker telmisartan induces apoptosis and autophagy in adult T-cell leukemia cells. FEBS Open Bio (2016) 0.76
Angiotensin II receptor blockers induce autophagy in prostate cancer cells. Oncol Lett (2017) 0.75
Tumor angiogenesis: therapeutic implications. N Engl J Med (1971) 35.36
Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med (1995) 26.60
Tumor angiogenesis: a new significant and independent prognostic indicator in early-stage breast carcinoma. J Natl Cancer Inst (1992) 8.69
Convergence of 9-cis retinoic acid and peroxisome proliferator signalling pathways through heterodimer formation of their receptors. Nature (1992) 6.69
PPAR-gamma: adipogenic regulator and thiazolidinedione receptor. Diabetes (1998) 6.53
Differential expression and activation of a family of murine peroxisome proliferator-activated receptors. Proc Natl Acad Sci U S A (1994) 6.46
Control of the peroxisomal beta-oxidation pathway by a novel family of nuclear hormone receptors. Cell (1992) 4.95
Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity. Hypertension (2004) 3.51
Activation of proliferator-activated receptors alpha and gamma induces apoptosis of human monocyte-derived macrophages. J Biol Chem (1998) 3.27
Ligand for peroxisome proliferator-activated receptor gamma (troglitazone) has potent antitumor effect against human prostate cancer both in vitro and in vivo. Cancer Res (1998) 2.67
PPARgamma induces cell cycle withdrawal: inhibition of E2F/DP DNA-binding activity via down-regulation of PP2A. Genes Dev (1997) 2.29
Angiotensin II type 1 receptor blockers. Circulation (2001) 2.09
Expression of peroxisome proliferator-activated receptors (PPARs) in human urinary bladder carcinoma and growth inhibition by its agonists. Int J Cancer (2003) 1.86
Role of host angiotensin II type 1 receptor in tumor angiogenesis and growth. J Clin Invest (2003) 1.79
15-deoxy-delta(12,14)-PGJ(2) induces synoviocyte apoptosis and suppresses adjuvant-induced arthritis in rats. J Clin Invest (2000) 1.64
Inhibition of human lung cancer cell growth by the peroxisome proliferator-activated receptor-gamma agonists through induction of apoptosis. Biochem Biophys Res Commun (2000) 1.52
Angiotensin II type I antagonist prevents pulmonary metastasis of murine renal cancer by inhibiting tumor angiogenesis. Cancer Res (2002) 1.37
Angiotensin II stimulates angiogenesis in the chorio-allantoic membrane of the chick embryo. Eur J Pharmacol (1991) 1.35
Angiotensin II type 1 receptor expression in human pancreatic cancer and growth inhibition by angiotensin II type 1 receptor antagonist. FEBS Lett (2001) 1.25
Angiotensin II type 1 receptor antagonist as an angiogenic inhibitor in prostate cancer. Prostate (2007) 1.24
Evidence for a novel angiotensin II receptor involved in angiogenesis in chick embryo chorioallantoic membrane. Am J Physiol (1993) 1.22
Expression of peroxisome proliferator-activated receptor (PPAR) in human prostate cancer. Prostate (2002) 1.13
15-Deoxy-Delta(12,14)-prostaglandin J(2), a ligand for peroxisome proliferator-activated receptor-gamma, induces apoptosis in JEG3 choriocarcinoma cells. Biochem Biophys Res Commun (1999) 1.11
Expression of peroxisome proliferator-activated receptor gamma in renal cell carcinoma and growth inhibition by its agonists. Biochem Biophys Res Commun (2001) 1.10
Angiotensin II type 1 receptor expression in human breast tissues. Br J Cancer (1997) 1.04
Angiotensin II type 1 receptor antagonist candesartan as an angiogenic inhibitor in a xenograft model of bladder cancer. Clin Cancer Res (2006) 0.98
Expression of peroxisome proliferator-activated receptors in human testicular cancer and growth inhibition by its agonists. Urology (2002) 0.94
Pilot study of angiotensin II receptor blocker in advanced hormone-refractory prostate cancer. Int J Clin Oncol (2005) 0.93
The effect of peroxisome proliferator-activated receptor-gamma ligand on urological cancer cells. Int J Mol Med (2003) 0.92
Polymorphisms in angiotensin II type 1 receptor and angiotensin I-converting enzyme genes and breast cancer risk among Chinese women in Singapore. Carcinogenesis (2004) 0.90
Angiotensin II receptor subtypes in the human renal cortex and renal cell carcinoma. J Urol (1994) 0.89
Old antihypertensives as novel antineoplastics: angiotensin-I-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists. Med Hypotheses (2002) 0.89
Angiotensin II-receptor antagonists: an overview. Am J Health Syst Pharm (2000) 0.87
Candesartan cilexetil: an angiotensin II-receptor blocker. Am J Health Syst Pharm (2000) 0.80
Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med (2010) 27.12
Phosphate-activated glutaminase (GLS2), a p53-inducible regulator of glutamine metabolism and reactive oxygen species. Proc Natl Acad Sci U S A (2010) 4.18
First-line gefitinib for patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutations without indication for chemotherapy. J Clin Oncol (2009) 4.05
The severity of ultrasonographic findings in nonalcoholic fatty liver disease reflects the metabolic syndrome and visceral fat accumulation. Am J Gastroenterol (2007) 4.01
Nonalcoholic fatty liver disease is a novel predictor of cardiovascular disease. World J Gastroenterol (2007) 2.71
p73 induction after DNA damage is regulated by checkpoint kinases Chk1 and Chk2. Genes Dev (2004) 2.07
Intracellular role for sphingosine kinase 1 in intestinal adenoma cell proliferation. Mol Cell Biol (2006) 2.04
Mutations in the SLC34A2 gene are associated with pulmonary alveolar microlithiasis. Am J Respir Crit Care Med (2006) 1.98
Excellent long-term outcome of ABO-incompatible living donor kidney transplantation in Japan. Am J Transplant (2004) 1.93
Expression of peroxisome proliferator-activated receptors (PPARs) in human urinary bladder carcinoma and growth inhibition by its agonists. Int J Cancer (2003) 1.86
Relationship of CD4+CD25+ regulatory T cells to immune status in HIV-infected patients. AIDS (2005) 1.76
Homozygosity haplotype allows a genomewide search for the autosomal segments shared among patients. Am J Hum Genet (2007) 1.76
Preoperative masked renal damage in Japanese patients with primary aldosteronism: identification of predictors for chronic kidney disease manifested after adrenalectomy. Int J Urol (2012) 1.61
Sphingosine 1-phosphate/sphingosine 1-phosphate receptor 1 signaling in rheumatoid synovium: regulation of synovial proliferation and inflammatory gene expression. Arthritis Rheum (2006) 1.59
The protective role of host Toll-like receptor-4 in acute graft-versus-host disease. Transplantation (2010) 1.59
Low molecular weight phenotype of Apo(a) is a risk factor of corticosteroid-induced osteonecrosis of the femoral head after renal transplant. J Rheumatol (2007) 1.50
Endogenous interleukin-6, but not tumor necrosis factor alpha, contributes to the development of toll-like receptor 4/myeloid differentiation factor 88-mediated acute arthritis in mice. Arthritis Rheum (2005) 1.47
Efficacy of naftopidil for nocturia in male patients with lower urinary tract symptoms: comparison of morning and evening dosing. Int J Urol (2014) 1.39
Rheumatoid arthritis after 9 years of human immunodeficiency virus infection: possible contribution of tritherapy. J Rheumatol (2002) 1.38
High phosphoantigen levels in bisphosphonate-treated human breast tumors promote Vgamma9Vdelta2 T-cell chemotaxis and cytotoxicity in vivo. Cancer Res (2011) 1.34
First-line gefitinib in patients aged 75 or older with advanced non-small cell lung cancer harboring epidermal growth factor receptor mutations: NEJ 003 study. J Thorac Oncol (2012) 1.33
Molecular evidence of interhuman transmission of Pneumocystis pneumonia among renal transplant recipients hospitalized with HIV-infected patients. Emerg Infect Dis (2004) 1.31
Excess HDM2 impacts cell cycle and apoptosis and has a selective effect on p53-dependent transcription. J Biol Chem (2006) 1.28
Contribution of IL-18 to atopic-dermatitis-like skin inflammation induced by Staphylococcus aureus product in mice. Proc Natl Acad Sci U S A (2006) 1.26
Expression of prostate-specific membrane antigen in normal and malignant human tissues. World J Surg (2006) 1.23
FTY720 versus mycophenolate mofetil in de novo renal transplantation: six-month results of a double-blind study. Transplantation (2007) 1.21
Short- and long-term donor outcomes after kidney donation: analysis of 601 cases over a 35-year period at Japanese single center. Transplantation (2009) 1.20
Subsequent skin cancers in kidney and heart transplant recipients after the first squamous cell carcinoma. Transplantation (2006) 1.15
NUB1 suppresses the formation of Lewy body-like inclusions by proteasomal degradation of synphilin-1. Am J Pathol (2006) 1.14
A three-arm study comparing immediate tacrolimus therapy with antithymocyte globulin induction therapy followed by tacrolimus or cyclosporine A in adult renal transplant recipients. Transplantation (2003) 1.13
Expression of peroxisome proliferator-activated receptor (PPAR) in human prostate cancer. Prostate (2002) 1.13
A prospective PCR-based screening for the EML4-ALK oncogene in non-small cell lung cancer. Clin Cancer Res (2012) 1.12
A case of renal cell carcinoma found after skin metastasis. Hinyokika Kiyo (2004) 1.08
Expression of lipoxygenase in human prostate cancer and growth reduction by its inhibitors. Int J Oncol (2004) 1.07
Telmisartan is a potent target for prevention and treatment in human prostate cancer. Oncol Rep (2008) 1.07
Correlation between salivary epidermal growth factor levels and refractory intraoral manifestations in patients with Sjögren's syndrome. Mod Rheumatol (2013) 1.06
Chromosomal variability of human mesenchymal stem cells cultured under hypoxic conditions. J Cell Mol Med (2012) 1.05
Peptide nucleic acid-locked nucleic acid polymerase chain reaction clamp-based detection test for gefitinib-refractory T790M epidermal growth factor receptor mutation. Cancer Sci (2008) 1.03
Effects of the novel immunosuppressant FTY720 in a murine rheumatoid arthritis model. Clin Immunol (2010) 1.02
Functionally distinct Gata3/Chd4 complexes coordinately establish T helper 2 (Th2) cell identity. Proc Natl Acad Sci U S A (2013) 1.01
Myeloid-derived suppressor cells play crucial roles in the regulation of mouse collagen-induced arthritis. J Immunol (2013) 1.01
Drug free REmission/low disease activity after cessation of tocilizumab (Actemra) Monotherapy (DREAM) study. Mod Rheumatol (2014) 1.01
A quantitatively-modeled homozygosity mapping algorithm, qHomozygosityMapping, utilizing whole genome single nucleotide polymorphism genotyping data. BMC Bioinformatics (2010) 1.00
Genome-wide analysis reveals unique regulation of transcription of Th2-specific genes by GATA3. J Immunol (2011) 0.99
Pneumatosis intestinalis and hepatic portal venous gas caused by gastrointestinal perforation with amyloidosis. J Clin Gastroenterol (2008) 0.99
Overexpression of cysteinyl LT1 receptor in prostate cancer and CysLT1R antagonist inhibits prostate cancer cell growth through apoptosis. Oncol Rep (2007) 0.97
Induction of cyclooxygenase-2 in monocyte/macrophage by mucins secreted from colon cancer cells. Proc Natl Acad Sci U S A (2003) 0.97
Identification of two novel female-specific non-major histocompatibility complex loci regulating collagen-induced arthritis severity and chronicity, and evidence of epistasis. Arthritis Rheum (2004) 0.97
A case of iatrogenic subclavian artery injury successfully treated with endovascular procedures. Ann Vasc Dis (2011) 0.96
Prediction of the pathogens that are the cause of pneumonia by the battlefield hypothesis. PLoS One (2011) 0.96
A critical role for allograft inflammatory factor-1 in the pathogenesis of rheumatoid arthritis. J Immunol (2007) 0.96
Management and outcome of living kidney grafts with multiple arteries. Surg Today (2005) 0.96
Interleukin-2 receptor antagonist induction in modern immunosuppression regimens for renal transplant recipients. Transpl Int (2006) 0.95
Copper chelation with tetrathiomolybdate suppresses adjuvant-induced arthritis and inflammation-associated cachexia in rats. Arthritis Res Ther (2005) 0.94
Expression of peroxisome proliferator-activated receptors in human testicular cancer and growth inhibition by its agonists. Urology (2002) 0.94
Expression of cyclooxygenase-1 and -2 in human breast cancer. Surg Today (2003) 0.93
Water-soluble extracts from Angelica acutiloba Kitagawa enhance hematopoiesis by activating immature erythroid cells in mice with 5-fluorouracil-induced anemia. Exp Hematol (2004) 0.93
The effect of peroxisome proliferator-activated receptor-gamma ligand on urological cancer cells. Int J Mol Med (2003) 0.92
ApoB C7623T polymorphism predicts risk for steroid-induced osteonecrosis of the femoral head after renal transplantation. J Orthop Sci (2007) 0.92
Reciprocal expression of MRTF-A and myocardin is crucial for pathological vascular remodelling in mice. EMBO J (2012) 0.92
Endoscopic resection for the diagnosis of visceral Kaposi's sarcoma. J Gastroenterol (2005) 0.92
Expression of lipoxygenase in human bladder carcinoma and growth inhibition by its inhibitors. J Urol (2003) 0.92
Chronic humoral rejection mediated by anti-HLA-DP alloantibodies: insights into the role of epitope sharing in donor-specific and non-donor specific alloantibodies generation. Transpl Immunol (2009) 0.91
5-Lipoxygenase inhibitors attenuate growth of human renal cell carcinoma and induce apoptosis through arachidonic acid pathway. Oncol Rep (2005) 0.91
Sphingosine 1-phosphate receptor activation enhances BMP-2-induced osteoblast differentiation. Biochem Biophys Res Commun (2012) 0.90
High predictive accuracy of Aldosteronoma Resolution Score in Japanese patients with aldosterone-producing adenoma. Surgery (2011) 0.90
Galectin-9 ameliorates acute GVH disease through the induction of T-cell apoptosis. Eur J Immunol (2010) 0.90
Can serum be used for analyzing the EGFR mutation status in patients with advanced non-small cell lung cancer? Am J Clin Oncol (2013) 0.90
Electro-transfer of small interfering RNA ameliorated arthritis in rats. Biochem Biophys Res Commun (2005) 0.90
Age dependence of early symptomatic vertebral fracture with high-dose glucocorticoid treatment for collagen vascular diseases. J Clin Endocrinol Metab (2009) 0.89
Combination analysis of three polymorphisms for predicting the risk for steroid-induced osteonecrosis of the femoral head. J Orthop Sci (2008) 0.89
Structure-function analysis of NADE: identification of regions that mediate nerve growth factor-induced apoptosis. J Biol Chem (2002) 0.89